TP53 and B-cell chronic lymphocytic leukemia: The E1912 study and the FLAIR study showed that ibrutinib + rituximab was more effective than FCR for patients 70 years or less without del(17p)/TP53 mutation, especially for those with unmutated IGHV, indicating that ibrutinib may be an appropriate option for younger patients with IGHV unmutated CLL as well [10].